• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Down 1%; Dave Shares Jump After Q4 Results

    3/5/24 2:11:52 PM ET
    $AISP
    $APGE
    $CNSL
    $DAVE
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AISP alert in real time by email

    U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 350 points on Tuesday.

    The Dow traded down 0.91% to 38,633.24 while the NASDAQ fell 1.85% to 15,906.92. The S&P 500 also fell, dropping, 1.05% to 5,076.98.

    Check This Out: Jim Cramer: This Semiconductor Company Is 'Too Late To Auto,' But Super Micro Is 'Too Hot'

     

    Leading and Lagging Sectors

     

    Energy shares rose by 1.3% on Tuesday.

    In trading on Tuesday, information technology shares fell by 2.2%.

     

    Top Headline

     

    Consolidated Communications Holdings Inc (NASDAQ:CNSL) posted a narrower-than-expected loss for its fourth quarter.

    The company reported a fourth-quarter fiscal 2023 revenue decline of 7.0% year-on-year to $275.2 million, missing the analyst consensus of $276.9 million. Adjusted loss of 26 cents beat the analyst consensus loss of 36 cents.

     

    Equities Trading UP

     

    Dave Inc. (NASDAQ:DAVE) shares shot up 51% to $32.99 after the company reported a year-over-year increase in fourth-quarter revenue results.

    Shares of Airship AI Holdings, Inc. (NASDAQ:AISP) got a boost, surging 87% to $3.08 after the company announced that it has been awarded a contract with the Department of Justice for its Acropolis Enterprise Sensor Management video and data management platform.

    Apogee Therapeutics, Inc. (NASDAQ:APGE) shares were also up, gaining 51% to $63.03 after the company announced interim results from its Phase 1 healthy volunteer trial for APG777. Also, the company reported FY23 financial results.

     

    Equities Trading DOWN

     

    Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) shares dropped 47% to $1.55 after the company announced the pricing of a $6.5 million public offering.

    Shares of ThredUp Inc. (NASDAQ:TDUP) were down 23% to $1.8150 after reporting fourth-quarter results.

    Crawford & Company (NYSE: CRD-A) was down, falling 27% to $9.13 after the company reported worse-than-expected fourth-quarter financial results.

    Also Check This Out: Wall Street's Most Accurate Analysts Say Buy These 3 Real Estate Stocks With Over 3% Dividend Yields

     

    Commodities

     

    In commodity news, oil traded down 1% to $77.95 while gold traded up 0.5% at $2,137.60.

    Silver traded rose 0.1% to $24.00 on Tuesday while copper fell 0.4% to $3.8435.

     

    Euro zone

     

    European shares closed mixed today. The eurozone’s STOXX 600 fell 0.23%, London’s FTSE 100 rose 0.08% while Spain’s IBEX 35 Index rose 0.47% The German DAX declined 0.10% French CAC 40 fell 0.30% while Italy’s FTSE MIB Index rose 0.71%.

    Industrial producer prices in the Eurozone fell by 8.6% year-over-year in January, compared to a revised 10.7% decline in the prior month. The eurozone services PMI rose to 50.2 in February versus a preliminary level of 50.

    The HCOB German services PMI was revised higher to 48.3 in February versus a preliminary reading of 48.2, while French services PMI climbed to 48.4 in February from 45.4 a month ago. The S&P Global UK services PMI was revised down to 53.8 in February compared to a preliminary reading of 54.3.

     

    Asia Pacific Markets

     

    Asian markets closed mostly lower on Tuesday, with Japan’s Nikkei 225 falling 0.03%, Hong Kong’s Hang Seng Index dipping 2.61%, China’s Shanghai Composite Index gaining 0.28% and India’s S&P BSE Sensex declining 0.26%.

    The Chinese government said it sees GDP increasing around 5% in 2024, unchanged from the previous year. The Caixin China general service PMI fell to 52.5 in February from 52.7 in January.

    The HSBC Indian services PMI fell to 60.6 in February from a preliminary reading of 62.0. The au Jibun Bank Japan services PMI rose to 52.9 in February versus preliminary reading of 52.5. The S&P Global Hong Kong SAR PMI fell to 49.7 in February versus 49.9 a month ago.

     

    Economics

     

    The Logistics Manager’s Index in the U.S. rose to a reading of 56.5 in February, notching the strongest reading in four months.

    The S&P Global services PMI was revised higher to 52.3 in February compared to a preliminary reading of 51.3.

    The S&P Global composite PMI rose to 52.5 in February versus a preliminary reading of 51.4.

    U.S. factory orders fell by 3.6% month-over-month in January compared to a revised 0.3% decline in December.

    The ISM services PMI declined to 52.6 in February versus a four-month high level of 53.4 in January and down from market estimates of 53.

    Now Read This: Wayfair, Snap And 2 Other Stocks Insiders Are Selling

    Get the next $AISP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AISP
    $APGE
    $CNSL
    $DAVE

    CompanyDatePrice TargetRatingAnalyst
    Dave Inc.
    $DAVE
    2/9/2026Outperform
    Keefe Bruyette
    Apogee Therapeutics Inc.
    $APGE
    1/22/2026$83.00Outperform → Sector Perform
    RBC Capital Mkts
    Apogee Therapeutics Inc.
    $APGE
    1/7/2026Peer Perform
    Wolfe Research
    Apogee Therapeutics Inc.
    $APGE
    12/17/2025$95.00Overweight
    Stephens
    Apogee Therapeutics Inc.
    $APGE
    12/10/2025$103.00Buy
    Deutsche Bank
    Apogee Therapeutics Inc.
    $APGE
    11/3/2025$109.00Buy
    Craig Hallum
    ThredUp Inc.
    $TDUP
    10/30/2025$11.00Buy
    Roth Capital
    Apogee Therapeutics Inc.
    $APGE
    10/21/2025$105.00Outperform
    Mizuho
    More analyst ratings

    $AISP
    $APGE
    $CNSL
    $DAVE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Keefe Bruyette initiated coverage on Dave, Inc.

    Keefe Bruyette initiated coverage of Dave, Inc. with a rating of Outperform

    2/9/26 7:01:11 AM ET
    $DAVE
    Finance: Consumer Services
    Finance

    Apogee Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Apogee Therapeutics from Outperform to Sector Perform and set a new price target of $83.00

    1/22/26 8:24:52 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Apogee Therapeutics

    Wolfe Research initiated coverage of Apogee Therapeutics with a rating of Peer Perform

    1/7/26 9:08:42 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AISP
    $APGE
    $CNSL
    $DAVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Allen Paul M. bought $274,270 worth of shares (100,000 units at $2.74), increasing direct ownership by 193% to 151,948 units (SEC Form 4)

    4 - Airship AI Holdings, Inc. (0001842566) (Issuer)

    12/30/25 9:00:14 AM ET
    $AISP
    Computer Software: Prepackaged Software
    Technology

    CEO and Chairman of the BOD Huang Victor bought $30,229 worth of shares (10,000 units at $3.02), increasing direct ownership by 5% to 204,849 units (SEC Form 4)

    4 - Airship AI Holdings, Inc. (0001842566) (Issuer)

    11/24/25 4:15:13 PM ET
    $AISP
    Computer Software: Prepackaged Software
    Technology

    CEO and Chairman of the BOD Huang Victor bought $161,986 worth of shares (51,000 units at $3.18), increasing direct ownership by 35% to 194,849 units (SEC Form 4)

    4 - Airship AI Holdings, Inc. (0001842566) (Issuer)

    11/20/25 5:10:58 PM ET
    $AISP
    Computer Software: Prepackaged Software
    Technology

    $AISP
    $APGE
    $CNSL
    $DAVE
    SEC Filings

    View All

    Airship AI Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Airship AI Holdings, Inc. (0001842566) (Filer)

    2/17/26 4:15:50 PM ET
    $AISP
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Airship AI Holdings Inc.

    SCHEDULE 13G/A - Airship AI Holdings, Inc. (0001842566) (Subject)

    2/17/26 4:13:03 PM ET
    $AISP
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-K filed by Airship AI Holdings Inc.

    10-K - Airship AI Holdings, Inc. (0001842566) (Filer)

    2/17/26 9:05:51 AM ET
    $AISP
    Computer Software: Prepackaged Software
    Technology

    $AISP
    $APGE
    $CNSL
    $DAVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apogee Therapeutics to Participate in Upcoming March Conferences

    SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 9:10 a.m. E.T. Management will also attend the UBS Biotech Summit Miami, Catalyst for Change on Monday, March 9, 2026, and the Jefferies Biotech on the Beach Summit on Tuesday, March 10, 2026. A live and archived webcast of the fireside chat at the TD Cowen Conference will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About ApogeeApogee Therapeutics is a clinical-stage biotechn

    2/24/26 7:30:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Airship AI Reports Fourth Quarter 2025 Financial Results

    Fourth Quarter 2025 Net Revenues of $6.5 Million, Gross Profit of $3.3 Million and Gross Margin of 51.2% Net Revenue Increase of 102% and Gross Margin Increase of 169% as Compared to Q4 of the Prior Year Cash flow positive business operations for the quarter. REDMOND, Wash., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Airship AI Holdings, Inc. (NASDAQ:AISP) ("Airship AI" or the "Company"), a leader in AI-driven video, sensor, and data management surveillance solutions, today reported its financial and operational results for the fourth quarter ended December 31, 2025. Q4 2025 Financial Highlights Net revenues for the quarter ended December 31, 2025, were $6.5 million.Gross profits for the qu

    2/17/26 9:00:00 AM ET
    $AISP
    Computer Software: Prepackaged Software
    Technology

    Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight

    The atopic dermatitis market is expected to grow, driven by the extensive market penetration of approved therapies for moderate-to-severe atopic dermatitis and the entry of new therapies such as OX40 inhibitor (Rocatinlimab [KHK4083/AMG451]), OX40L inhibitor (Amlitelimab [KY1005]), PDE4 inhibitor (Orismilast), TSLP inhibitor (Bosakitug [BSI-045B]), IL-22RA1 blocker (Temtokibart [LP0145; LEO 138559]), IL-4Rα blocker (Rademikibart [CBP-201]), and others.LAS VEGAS, Feb. 16, 2026 /PRNewswire/ -- Recently published Atopic Dermatitis Market Insights report includes a comprehensive understanding of current treatment practices, atopic dermatitis emerging drugs, market share of individual therapies,

    2/16/26 5:31:00 PM ET
    $ABBV
    $AMGN
    $APGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Commercial Physical & Biological Resarch

    $AISP
    $APGE
    $CNSL
    $DAVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Henderson Michael Thomas sold $1,266,953 worth of shares (20,000 units at $63.35), decreasing direct ownership by 2% to 1,172,987 units (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    2/13/26 8:00:15 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Financial Officer Lawlor Sally Bridget

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    2/6/26 5:24:03 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Cooper Joseph Patrick

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    2/6/26 5:21:52 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $AISP
    $APGE
    $CNSL
    $DAVE
    Financials

    Live finance-specific insights

    View All

    Dave Reports Preliminary Fourth Quarter and Full Year 2025 Results

    2025 Revenue and Adjusted EBITDA Results are Expected to Exceed the Top-End of Guidance 4Q25 28 DPD Rate Expected to be Within the Range of 1.95%-2.00%, Outperforming Guidance of Below 2.10% Full Earnings Results and 2026 Financial Outlook to Be Discussed on March 2, 2026 at 5:00pm ET LOS ANGELES, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced certain preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company expects to release full, audited financial results and file its annual report on Form 10-K for the year ended December 31, 2025 on Mar

    2/5/26 4:15:00 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    ThredUp to Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026

    OAKLAND, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- ThredUp (NASDAQ:TDUP, LTSE: TDUP)), one of the largest online resale platforms for apparel, shoes, and accessories, announced today that its financial results for the fourth quarter and full year ended December 31, 2025 will be released on Monday, March 2, 2026 after the close of the U.S. markets. ThredUp will host a conference call and live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. The live and archived webcast and all related earnings materials will be available at ThredUp's investor relations website: ir.thredup.com/news-events/events-and-presentations. About ThredUp ThredUp is transforming resale with technology and a mission

    2/2/26 4:05:00 PM ET
    $TDUP
    Catalog/Specialty Distribution
    Consumer Discretionary

    Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

    Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available follow up - Results reinforce continued development in asthma testing every 3- or 6-month dosing Successful expansion of zumilokibart beyond dermatology confirms its pipeline-in-a-product potential across I&I indications Zumilokibart in atopic dermatitis (AD) advancing in Phase 2 APEX trials with goal of Phase 3 initiation by end of 2026:- Part A maintenance (52-week) data readout expected in Q1 2026 with potential to establish best-in-class e

    1/6/26 6:00:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AISP
    $APGE
    $CNSL
    $DAVE
    Leadership Updates

    Live Leadership Updates

    View All

    Dave Inc. Appoints Nima Khajehnouri to Board of Directors; Announces Board Leadership Transitions

    LOS ANGELES, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced that Nima Khajehnouri, a distinguished leader in artificial intelligence and data engineering, has joined its Board of Directors, effective immediately. Mr. Khajehnouri will serve as a member of the Company's Audit Committee. Imran Khan, who has served on the Board since August 2023, is stepping down in conjunction with this appointment. Mr. Khajehnouri brings more than two decades' experience of leading engineering at some of the world's most influential technology companies. He currently serves as Vice President of Engineering at Meta, h

    1/20/26 5:27:46 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    ThredUp Appoints Financial Governance Leader Kelly Bodnar Battles to Board of Directors and Audit Committee Chair

    Financial Leader to Bolster Oversight During Period of Accelerated Growth ThredUp (NASDAQ:TDUP, LTSE: TDUP)), one of the largest online resale platforms for apparel, shoes, and accessories, today announced the appointment of Kelly Bodnar Battles to its Board of Directors, with the appointment becoming effective on December 1, 2025. Upon the effective date, Battles will assume the role of Audit Committee Chair. This appointment reinforces ThredUp's continued commitment to strengthening its financial governance as the company accelerates its growth and transformation into an AI-first resale marketplace. This press release features multimedia. View the full release here: https://www.busines

    11/17/25 4:05:00 PM ET
    $ANET
    $TDUP
    Computer Communications Equipment
    Telecommunications
    Catalog/Specialty Distribution
    Consumer Discretionary

    Dave Appoints Parker Barrile as Chief Product Officer

    Los Angeles, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced the appointment of Parker Barrile as Chief Product Officer, effective November 10. Parker brings executive-level product leadership experience from Prosper and LinkedIn in building and scaling consumer and financial technology businesses. He also brings an investor mindset, having spent the last nine years as a partner at Norwest, where he led Dave's Series B fundraise and served on the Company's Board of Directors. Parker will report directly to Dave's founder and CEO, Jason Wilk. As Chief Product Officer, Parker will lead Dave's product

    10/29/25 8:00:00 AM ET
    $DAVE
    Finance: Consumer Services
    Finance

    $AISP
    $APGE
    $CNSL
    $DAVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.

    SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

    11/14/24 5:46:11 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by ThredUp Inc.

    SC 13G - ThredUp Inc. (0001484778) (Subject)

    11/14/24 12:15:58 PM ET
    $TDUP
    Catalog/Specialty Distribution
    Consumer Discretionary